Safety and Effects of Ramipril Combined With Candesartan
Phase 4
Completed
- Conditions
- Hypertension
- Registration Number
- NCT00356395
- Lead Sponsor
- Gachon University Gil Medical Center
- Brief Summary
we hypothesized that combination therapy has additive beneficial effects to improve endothelial dysfunction and adipocytokine profiles in patients with hypertension.
- Detailed Description
Forty patients will be given ramipril 10 mg and placebo, ramipril 10 mg and candesartan 16 mg, or candesartan 16 mg and placebo daily in a randomized, double-blind, placebo-controlled cross-over trial with three treatment arms and two washout periods (each 2 months).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- patients with mild to moderate hypertension
Exclusion Criteria
- We will exclude patients with severe hypertension, unstable angina, acute myocardial infarction, or renal insufficiency.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method comparison of endothelium-dependent dilation among the 3 treatment schemes
- Secondary Outcome Measures
Name Time Method